DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Whether Med-QUEST covers Wegovy, Zepbound, Ozempic, or Mounjaro for weight loss and type 2 diabetes, prior authorization rules, and routes when coverage is denied.
Med-QUEST conservative on weight-loss; T2D well-supported. Submit prior authorization through your prescriber, not directly. Approval decisions typically take 3-10 business days; expedited reviews for urgent cases process within 72 hours. Denials are appealable; first-round appeals succeed roughly 30-40% of the time when supporting documentation is thorough.
If Med-QUEST denies coverage, the practical routes are: (1) manufacturer cash-pay channels like NovoCare Direct (Wegovy at $499/month) and LillyDirect (Zepbound at $549/month), (2) compounded semaglutide or tirzepatide via telehealth (lower price but not FDA-approved; supply tightening after the May 2026 shortage resolution), or (3) charity care through patient assistance programs offered by Novo Nordisk and Eli Lilly for low-income patients.
Island telehealth heavily promoted; rural-equivalent expansion. Major telehealth providers operating in Hawaii include ro body, form health.
Pharmacy supply chain to islands occasionally affects fill speed.
Editorial summary, not legal or medical advice. State Medicaid policies change frequently. Confirm current status with Med-QUEST member services or your prescriber.